[HTML][HTML] Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP …
The BEBYP trial is a prospective, randomized, open-label, multicenter, phase III study
evaluating the continuation or reintroduction of bevacizumab with second-line …
evaluating the continuation or reintroduction of bevacizumab with second-line …
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial.
G Masi, L Salvatore, L Boni, F Loupakis… - Annals of Oncology …, 2015 - europepmc.org
Background The combination of bevacizumab with fluorouracil-based chemotherapy is a
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, F Loupakis… - Annals of …, 2015 - annalsofoncology.org
The BEBYP trial is a prospective, randomized, open-label, multicenter, phase III study
evaluating the continuation or reintroduction of bevacizumab with second-line …
evaluating the continuation or reintroduction of bevacizumab with second-line …
[PDF][PDF] Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP …
G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini… - 2015 - Citeseer
Background: The combination of bevacizumab with fluorouracil-based chemotherapy is a
standard first-line treatment option in metastatic colorectal cancer. We studied the efficacy of …
standard first-line treatment option in metastatic colorectal cancer. We studied the efficacy of …
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial
A Falcone, L Salvatore, L Boni, F Loupakis… - ANNALS OF …, 2015 - arpi.unipi.it
Background: The combination of bevacizumab with fluorouracil-based chemotherapy is a
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
[PDF][PDF] Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP …
G Masi, L Salvatore, L Boni, F Loupakis, C Cremolini… - 2015 - researchgate.net
Background: The combination of bevacizumab with fluorouracil-based chemotherapy is a
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
[引用][C] Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP …
G Masi, L Salvatore, L Boni, F Loupakis… - Annals of …, 2015 - cir.nii.ac.jp
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in
metastatic colorectal cancer: final results of the randomized BEBYP trial | CiNii Research …
metastatic colorectal cancer: final results of the randomized BEBYP trial | CiNii Research …
[引用][C] Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP …
G Masi, A Falcone, L Salvatore, F Loupakis… - Annals of …, 2015 - elibrary.ru
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni… - Annals of oncology …, 2015 - pubmed.ncbi.nlm.nih.gov
Background The combination of bevacizumab with fluorouracil-based chemotherapy is a
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: Final results of the randomized BEBYP trial
G Masi, L Salvatore, L Boni, F Loupakis… - ANNALS OF …, 2015 - flore.unifi.it
Background: The combination of bevacizumab with fluorouracil-based chemotherapy is a
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …
standard first-line treatment option in metastatic colorectal cancer (mCRC). We studied the …